Scientists have developed a new type of blood test that may improve how Alzheimer’s disease is detected and understood.
Unlike most current blood tests, which measure how much of certain proteins are present, this new method looks at how the structure of proteins changes.
These structural changes may reveal deeper information about what is happening inside the brain. The findings were published in the journal Nature Aging.
Alzheimer’s disease is the most common cause of dementia. It slowly damages memory, thinking, and behavior. As the disease progresses, people may struggle with daily tasks, communication, and decision-making. For many years, doctors have relied on brain scans, spinal fluid tests, and memory exams to diagnose Alzheimer’s.
More recently, blood tests have been developed to measure proteins linked to the disease. These tests are easier and less invasive, but they mainly focus on the amount of specific proteins in the blood.
The new study takes a different approach. Instead of simply measuring protein levels, researchers examined how the shape and structure of certain proteins change in people with Alzheimer’s. In many diseases, including Alzheimer’s, proteins can become misfolded.
When proteins lose their normal shape, they may not function properly. In the brain, misfolded proteins can build up and form harmful clumps that damage nerve cells.
The research was supported by scientists working with the National Institute on Aging. Dr. Richard Hodes, director of the institute, said this study introduces a new blood-based way to detect and stage Alzheimer’s disease.
He explained that by focusing on structural changes in proteins, the test may capture biological features that current blood tests cannot detect. These include links to genetic risk, symptom severity, and differences between men and women.
To explore this idea, researchers analyzed blood plasma samples from 520 volunteers. The participants included people diagnosed with Alzheimer’s disease, people with mild cognitive impairment, and healthy individuals.
Mild cognitive impairment is a condition where someone has noticeable memory problems but does not yet meet the criteria for dementia. The participants were seen at Alzheimer’s Disease Research Centers in Kansas and California and underwent regular evaluations.
The team used a technique called mass spectrometry, which allows scientists to examine proteins in great detail. They combined this with machine learning, a computer-based method that can identify patterns in large amounts of data.
By studying the structure of proteins in the blood, the researchers found changes linked to variations in the ApoE gene. Certain forms of the ApoE gene are known to increase the risk of Alzheimer’s disease.
The researchers also discovered that protein structural changes were connected to the severity of neuropsychiatric symptoms. These symptoms can include depression, anxiety, agitation, and mood changes. Interestingly, the study found different structural patterns in men and women.
This may help explain why some symptoms appear more often or more strongly in one sex compared to the other.
Using their findings, the team developed a diagnostic panel based on three proteins: C1QA, CLUS, and ApoB. Rather than measuring how much of these proteins was present, the test focused on structural disruptions linked to Alzheimer’s.
The panel was able to distinguish between people with Alzheimer’s, those with mild cognitive impairment, and healthy controls. It also showed potential for tracking disease progression over time.
Dr. John Yates, the lead author of the study and a professor at The Scripps Research Institute, said this approach uncovers structural disruptions in proteins that traditional methods miss.
Because the test can help separate different stages of the disease, it may support earlier diagnosis. Earlier detection is important because treatments are likely to be more effective before significant brain damage occurs.
When reviewing these findings, several strengths stand out. The study included a relatively large number of participants and used advanced tools to examine protein structure in detail. The ability to connect protein changes with genetic risk and symptom differences between men and women adds depth to the research.
However, there are also limitations. The test still needs validation in larger and more diverse populations. It is not yet clear how it will perform in routine clinical settings. In addition, while the results are promising, further studies are required before the test can become widely available.
Overall, this research represents an important step forward in Alzheimer’s detection. By moving beyond simple protein measurements and examining structural changes, scientists may gain a clearer picture of how the disease develops and progresses.
If confirmed in future studies, this new blood-based biomarker panel could improve early diagnosis, help guide treatment decisions, and strengthen clinical trials aimed at slowing or preventing Alzheimer’s disease.
If you care about Alzheimer’s, please read studies about the likely cause of Alzheimer’s disease , and new non-drug treatment that could help prevent Alzheimer’s.
For more health information, please see recent studies about diet that may help prevent Alzheimer’s, and results showing some dementia cases could be prevented by changing these 12 things.
Copyright © 2026 Knowridge Science Report. All rights reserved.
